ArticleFrontiers in immunology2026
Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy.
Peter May et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.